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Abstract Multimorbidity, or the presence of several medical conditions in
the same individual, have been increasing in the population both in abso-
lute and relative terms. However, multimorbidity remains poorly understood,
and the evidence from existing research to describe its burden, determinants
and consequences have been limited. Many of these studies are often cross-
sectional and do not explicitly account for multimorbidity patterns’ evolution
over time. Some studies were based on small datasets, used arbitrary or narrow
age range, or lacked appropriate clinical validations. In this study, we applied
Non-negative Matrix Factorisation (NMF) in a novel way to one of the largest
electronic health records (EHR) databases in the world (with 4 million pa-
tients), for simultaneously modelling disease clusters and their role in one’s
multimorbidity over time. Furthermore, we demonstrated how the temporal
characteristics that our model associates with each disease cluster can help
mine disease trajectories/networks and generate new hypotheses for the for-
mation of multimorbidity clusters as a function of time/ageing. Our results
suggest that our method’s ability to learn the underlying dynamics of diseases
can provide the field with a novel data-driven / exploratory way of learning
the patterns of multimorbidity and their interactions over time.
Keywords Non-negative Matrix Factorisation · Multimorbidity · Disease
Trajectories · Electronic Health Records.
1 Introduction
Multimorbidity is generally defined as the presence of two or more chronic
conditions in an individual [46]. There is growing evidence that the number
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of people with multimorbidity has been increasing in many populations, both
in relative and absolute terms. This increasing burden has been attributed
to a number of factors, including the trend towards an ageing population
demographics, as well as factors relating to changes in lifestyle, health-seeking
behaviour and the environment [44]. Research in this area has been growing,
but most investigations have focused on predicting, preventing and managing
disorders in isolation from one another. Therefore, more research is needed for
a better understanding of this emerging burden, and its underlying patterns
and mechanisms, in order to anticipate its consequences for the health services
and the provision of appropriate care [32].
Different studies in the past have tried different methods to investigate the
multimorbidity patterns (MMPs). The first group of such analyses are based
on simple correlation/correspondence analyses, carried out on disease pairs;
we refer to them as “pairwise methods”. For instance, Goldacre et al. [9] at-
tempted to identify disease pairs, which show co-occurrence frequencies that
are different from what their individual frequencies in the population would
predict; disease pairs with higher or lower co-occurrences were interpreted as
associated or dissociated, respectively. Hidalgo et al [11] took pairwise meth-
ods further and built a disease network where the presence of an edge between
two nodes (i.e., diseases) represented a strong correlations between them in
the population they studied. They then showed the associations between the
“connectedness” of the nodes and mortality. In a slightly different pairwise
method that takes time into account, Jensen et al. [14] derived associations
of disease pairs by taking into account the order in which they occur. They
defined a concept called “disease trajectory clusters”, which can be viewed as
a directed network, where each node represents a disease and an edge from
disease A to B means that in many patients, B happened after A. Liu et al. [23]
employed a slightly different pairwise method; they formed a network where
nodes were medications, tests and diagnoses, and each edge’s weight and di-
rection denoted an interval between the occurrence of the concepts and their
order, respectively.
While pairwise methods are valuable in generating comorbidity hypothe-
ses for disease pairs, their use to form large networks (and the use of resulting
networks’ properties to draw medical conclusions) is likely to give misleading
results. That is, when considering two diseases, there are other confounding
diseases that are related to both diseases; this is known as the difference be-
tween correlation and partial correlation analysis [41]. This led to the rise of
a second category of methods for the study of MMPs, which we refer to as
“probabilistic methods”. In one of the earliest works in this category, Strauss
et al. [42] used latent class growth analysis to identify clusters of multimorbid-
ity trajectories but their analysis was based on a 3-year study period which
is a relatively short time for the study of MMPs; furthermore, their study of
temporal patterns was limited to counting chronic conditions recorded over
time (rather than the study of how one disease’s occurrence is associated with
other diseases’ occurrence). Wang et al. [50], on the other hand, used a Hidden
Markov Model to study the generative process underlying the disease trajec-
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tories. In their approach, the future relationship between latent comorbidity
variables and observed diseases are determined by the current relationship be-
tween them over time. The key challenge of this approach is its high sensitivity
to the current state of the model (rather than having a longer memory) and
its computational complexity/expensiveness.
Another category of methods use deep learning to extract insights from
EHRs. Many of these studies do not explicitly account for temporal informa-
tion [45,25]. Nguyen et al. [27] introduced a CNN architecture called Deepr
(Deep record), where a patient’s journey is modelled as a long sentence of
medical codes where time between events are denoted as “special words”. The
authors validated their method on hospital data to predict unplanned read-
mission after discharge. Another notable work is RETAIN (REverse Time At-
tentIoN) model by Choi et al. [3] which used two RNNs and a two-level neural
attention model to process sequential data using an end-to-end approach that
has been tested on predicting heart failure diagnosis. Many recent works pro-
posed similar architectures for different prediction tasks, including patients’
readmission [35,54], treatment recommendation [18] and personalized prescrip-
tion [49]. Although deep learning methods usually minimise the need for pre-
processing and feature engineering, the disease representations/associations
they generate are biased toward the prediction task and are not necessarily
generalisable to other tasks [53].
The other category of advanced methods that have been used to study
multimorbidity, is primarily based on matrix/tensor decomposition and factor
analysis; we refer to them as “factor methods”. In these methods, one usu-
ally starts by forming a matrix, where the entry i, j denotes a metric related
to disease i (or other concepts in EHR, such as medication and/or clinical
measurements) in patient j; factor methods decompose such a matrix into P
multimorbidity patterns. The resulting MMPs are described with two vectors:
Disease clusters (that show the influence of each disease in that MMP), and
the expression of that MMP in each patient. There have been multiple MMP
analyses that used factor methods, but they did not take into account the
temporal aspect of the diseases’ (co)occurrence and have been mostly limited
to the study of disease clusters [13,39,24,17,38]. As one of the exceptions
among factor methods, Zhou et al. [56] introduced a factor method that con-
siders the temporal patterns in electronic health record (EHR) data; while
the method has the potential to result in multimorbidity analyses, the study’s
primary focus was on the prediction of future diseases. Given the non-negative
nature of the data that such factor methods start from, non-negative factori-
sation techniques have also been used in this space. For instance, in both [12]
and [51], non-negative tensor factorisation have been employed to learn the
core factors underlying disease co-occurrences. If one represents the data to
such tensor factorisation techniques in certain ways, these techniques have the
ability to mine disease clusters and their temporal patterns. However, instead
of time the focus was on joint patterns of phenotypes such as medication and
diagnosis.
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Table 1: The key papers dealing with the analysis of multimorbidity and dis-
ease trajectories
Paper (year) Methodology #patients Handling of tempo-
ral trajectory
Age range
Goldacre et al.
(2000) [9]
Rate of co-occurrence 2.5 million For some diseases All
Hidalgo et al.
(2009) [11]
Network based on
pairwise correlations
13 million As a subsequent anal-
ysis
≥ 65
Wang et al.
(2012) [48]
NMF 21K (all diabetic) Up to one year All
Jensen et al.
(2014) [14]
Network based on
pairwise correlations
6.2 million 5-year window All
Strauss et al.
(2014) [42]
Latent class growth
modelling
24,615 Over 3 years > 50
Wang et al.
(2014) [50]
Hidden Markov Model 300,000 Over 4 years All
Nguyen et al.
(2017) [27]
Deep learning 300K Through discretising NA
Choi et al.
(2016) [3]
Deep learning 263K Yes 50 to 80
years
Rafiq et al.
(2018) [35]
Deep learning 610 Yes 70 to 80
years
Xiao et al.
(2018) [54]
Deep learning Heart Failure cohort
of 5,393 patients
Yes NA
Le et al. (2018)
[18]
Deep learning 6K and 5K Yes ≥ 16
Ho et al. (2014)
[12]
NMF 10,000 None ≥ 65
Zhou et al.
(2014) [56]
QR factorisation 249 and 187 Up to 20 years All
Wang et al.
(2015) [51]
NMF 7,744 and 472,645 None All
Liu et al. (2015)
[23]
Decomposition of ad-
jacency matrix of dis-
ease temporal graph
319,650 Over 4 years All
In summary, various investigations have attempted to mine the MMPs from
various sources of medical data - see Table 1. Most of these studies are lim-
ited to certain age ranges and/or are cross-sectional by design, which hampers
their ability to observe the patients over an appropriate amount of time to
see the temporal patterns of multimorbidity. Furthermore, in almost all these
methods, time was not taken into account; a few of them that did account for
progression over time, lacked appropriate MMP analysis and clinical valida-
tion (e.g., focused on disease prediction instead). For instance, in one of the
most powerful factor methods (in terms of taking time into account), Wang
et al. [48] used non-negative matrix factorisation (NMF), where each factor
has a temporal evolution model; while this approach has the potential to pro-
vide unique insights into diseases trajectories and their interactions, it has
only been validated on 21K patients with diabetes (i.e., limited data and clin-
ical focus). Therefore, there is still need for an investigation of MMPs, using
large datasets (that are representative of the population) and over a reason-
able time horizon, which can simultaneously model disease clusters and their
relationships/trajectories over time. The rapid growth in the development of
healthcare information systems has led to an increased interest in utilising
EHR. The longitudinal nature of EHR and its richness (e.g., containing diag-
noses, medications, and tests/measurement) can provide a unique opportunity
to study long-term patterns of diseases’ cooccurrence.
In this study, we apply NMF [4,8] (with a novel design that results in
both disease clusters and their trajectories) to one of the world’s largest EHR
datasets. Our approach (which falls in the factor method category) results in
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two main characteristics for each MMP (or factor): a disease cluster (which like
past factor methods is a vector showing the influences from each disease in that
MMP) and the expression of that MMP in each patient at a given age. The
expression of each MMP at a given age is the most important contribution of
our paper; to demonstrate its importance, we carried out a follow-up analysis
of building a multimorbidity network, where nodes are MMPs and an edge
between two MMPs denotes their associations and/or likely influence on each
other. The clinical validation of our results suggests that this new approach
provides the field with a unique tool to study complex multimorbidity networks
and their evolution as one ages.
2 Materials and methods
In this study, we are interested in understanding the MMPs, both in terms of
disease clusters (i.e., disease co-occurrence patterns) and how they influence
each other over time (i.e., their trajectories). In this section, we explain the
source of our data, our use of NMF, and the follow-up analyses we carried out
to show the strength of this approach as a foundation for future multimorbidity
research. Note that, for the rest of the paper, matrices will be denoted by upper
case bold fonts (e.g., A), vectors will be denoted by lower case bold fonts (e.g.,
a), and everything else (scalar and indices) will be denoted with no bolding of
the fonts.
2.1 Data
In this study, we used CPRD (Clinical Practice Research Datalink) [5]; it
contains longitudinal primary care data from a network of 674 general physi-
cian (GP) practices in the UK, and is linked to secondary care (i.e., Hospital
Episode Statistics, or HES) and other health and administrative databases
(e.g., office for national statistics’ death registration). Around 1 in 10 GP
practices in the UK contribute data to CPRD; it covers 35 million patients,
among whom nearly 10 million are currently registered patients. CPRD is
broadly representative of the population by age, sex, and ethnicity [10]. It has
been extensively validated and is considered as the most comprehensive lon-
gitudinal primary care database [47], with several large-scale epidemiological
reports [6,7,40] adding to its credibility.
HES, on the other hand, contains data on hospitalisations, outpatient vis-
its, accident and emergency for all admissions to National Health Service
(NHS) hospitals in England [21]. Approximately 75% of the CPRD GP prac-
tices in England (58% of all UK CPRD GP practices) participate in patient-
level record linkage with HES, which is performed by the Health and Social
Care Information Centre [26]. In this study, we only considered the data from
GP practices that consented to (and hence have) record linkage with HES.
The importance of primary care at the centre of the national health system in
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Table 2: The number of diseases in each level of ICD-10 hierarchy
Level Count Example
ICD-10 chapter 22 II Neoplasms
ICD-10 sub-chapter 211 C00-C97 Malignant neoplasms
ICD-10 2 digits level 2049 C00 Malignant neoplasm of lip
ICD-10 full code 10138 C00.0 Malignant neoplasm: External upper lip
the UK, the additional linkages, and all the aforementioned properties, make
CPRD one of the most suitable EHR datasets in the world for data-driven
clinical/medical discovery and machine learning.
2.2 Study Population
In order to have a comprehensive coverage of patients’ health journey, we only
considered the CPRD patients with at least 5 years of follow-up; this resulted in
a total number of 2,204,178 patients with a total number of clinical 25,791,493
encounters. Note that, in this study, we are interested in “incident cases” and
not in the “prevalent cases” of diseases, i.e. new occurrences of diseases rather
than diseases carried over. Therefore, we only considered the first occurrence
of each disease happening after 1 year of any patient’s registration date with
the general practice clinic (as the first year after registration is likely to contain
diseases carried over rather than new occurrences of diseases).
Another important step in processing CPRD was to create a consistent
diseases classifications between GP and HES data and choosing the appropri-
ate level of granularity in diseases’ hierarchy (see Table 2). In HES, diseases
are coded using ICD-10 (International Classification of Diseases [52]) code,
whereas in the GP records diseases are coded using Read Code [28]. ICD
offers a hierarchical form that makes its use for data mining and machine
learning much more convenient. Therefore, we decided to map the diseases to
the ICD domain, i.e., we mapped the Read Codes to ICD-10 codes using the
mapping provided by NHS Digital [29]. When no direct mapping was available,
Read Codes were first mapped to SNOMED-CT codes [31] (also provided by
NHS Digital [30]), and the latter are then mapped to ICD-10 codes using the
mapping provided by the US National Library of Medicine [33].
As mentioned earlier, ICD-10 codes are organised in a tree-like hierarchy.
Working at the highest level of the ICD-10 hierarchy will result in only a
few diseases and hence is not likely to help unravel the complex underlying
dependencies among diseases. Conversely, working at the lowest level of the
hierarchy will generate thousands of diseases, each with small number of oc-
currences (and even a smaller number of co-occurrences) and hence an overall
difficulty of mining useful inter-disease patterns. In this study, similarly to the
work in [38], we chose to work at the ICD-10 sub-chapter level, which pro-
vides a good trade off between granularity and co-occurrence, and can lead to
medically interpretable results. Furthermore, for the purpose of this study, we
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eliminate all the diagnoses relating to pregnancy, general symptoms, external
causes and administration (ICD-10 chapters XV, XVI, XVIII, XIX, XX and
XXI); similar to [14]. The resulting 142 ICD-10 sub-chapters are what we will
refer to as diseases from here on. the details of our inclusion/exclusion process
is shown in Figure 1.
• 1,090,697,736 clinical events
• 7,586,351 patients
• 413,253,939 clinical events
• 7,464,815 patients
Events with read code to 
ICD-10 mapping
Clinical GP data
• 413,253,939 clinical events
• 7,464,815 patients
Up-to-standard events
• 216,446,302 clinical events
• 4,343,301 patients
Linkage to HES eligibility
• 197,742,812 clinical events
• 4,310,355 patients
Events between CRD and TOD
• 189,073,334 clinical events
• 4,310,355 patients
Dropping duplicates events
• 18,345,125 clinical events
• 2,811,306 patients
HES data
• 17,189,6523 clinical events
• 3,907,665 patients
Dropping events within 1 
year of crd
• 165,148,562 clinical events
• 3,834,743 patients
Events between 01/01/1985 
and 31/12/2014
Dropping duplicates events
• 18,330,864 clinical events
• 2,811,306 patients
+
• 183,479,426 clinical events
• 4,078,742 patients
Combined GP and HES data
• 75,651,591 clinical events
• 3,799,201 patients
Relevant ICD-10 chapters
• 64,826,981 clinical events
• 2,204,178 patients
Patients with at least 5 years 
of follow-up  and only first 
occurrence of each disease
CPRD: Clinical Practice Research Datalink
HES: Hospital Episode Statistics
CRD: current registration date
TOD: transfer out date
Fig. 1: Inclusion/exclusion criteria for the study. In order to make sure that
the data is appropriate for the study’s objectives (described at the end of
Section 1), we made sure that patients whose records meets our criteria (in
terms of length, diseases, and quality of linkage) are only included. Also note
that, terms such as “up to standard”, “crd” and “tod” are referring to fields in
CPRD data; for more details on these, we refer readers to CPRD manual [5].
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After all these, our cut of CPRD dataset includes nearly 2.2M adult pa-
tients (aged 16 years and over) and 65M events; from here, this will be referred
to as the data in this study. Figure 2 shows some of the key characteristics
of the data. When compared to the studies in Table 1, in terms of number of
patients, length of follow-up and being representative of the population, our
data is comparable, if not better, than the best ones studied so far.
2.3 Non-negative Matrix Factorisation
Non-negative matrix factorisation (NMF, or NNMF) refers to a group of al-
gorithms that decompose a matrix D into (usually) two matrices A and B,
with the property that all three matrices have no negative elements, i.e.,
D ≈ A×B | A ≥ 0,B ≥ 0. (1)
This non-negativity makes the resulting matrices easier to inspect and in-
terpret. Also, in applications such as processing of count data (i.e., the starting
point of our multimorbidity analysis), non-negativity is inherent to the data
being considered. Since the NMF problem does not have an exact analytical so-
lution in general, there has been a range of numerical approximations for it [20,
22,19,15,2,55,1,57,43,16]. In this paper, we use the Kullback-Leibler diver-
gence and simple multiplicative updates [20,19], enhanced to avoid numerical
underflow [2] as implemented by Nimfa python package [57]. Furthermore, in
order to determine the number of factors (or, as in our analysis, the number
of MMPs), we used the commonly applied cophenetic correlation coefficient,
which measures the stability of clustering associated with a given rank [2].
2.4 Modelling Pipeline
We start our modelling pipeline by forming a “disease matrix” Dp for each
patient p, where entry di,j is 1 if patient p had the first incidence of disease i
at age (in years) j; di,j will be 0 otherwise. This makes Dp a T × C matrix,
where C is the number of conditions/diseases (i.e., 142 in our case) and T is
the maximum age we track a patient for (i.e., 114 years in our case). Denoting
the total number patients by N , this process will result in N such Dp matrices.
We carry out two processing steps to create a final disease matrix D for the
NMF analysis.
Given the variability in disease prevalences (i.e., some diseases are more
common than others), the counts corresponding to rarer diseases (such as
tuberculosis) are expected to be much lower than the counts corresponding
to more common diseases such (such as respiratory infections). Therefore,
when solving the NMF model, the results can be biased towards explaining
the more frequent diseases/the higher counts. In order to correct for this, in
our first processing step, we used an adjustment inspired by TF-IDF (term
frequency-inverse document frequency) which is commonly used in natural
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language processing and information retrieval tasks [36]. More specifically, we
introduce DF-IPF (disease frequency - inverse patient frequency), which equals
DF × IPF , where we set DF = 1 as we only considered the first occurrence
of each disease. For each disease i, we then defined
IPF (i) = log
N
#patients who had disease i
, (2)
where N is the total number of patients in our study. The DF-IPF adjust-
ment for Dp will simply result from the multiplication of its entries with the
appropriate inverse patient frequency (i.e., di,j ← di,j ∗ IPF (i)).
As each patient will only have a small subset of diseases, Dp is expected to
be sparse. On the other hand, NMF does not explicitly model age as a temporal
concept with a covariance structure (i.e., no explicit model for the relationship
among rows in D). In medicine, however, one will not see a meaningful dif-
ference between a disease happening at age a or a±one or two years; they are
virtually the same. In factorisation of a matrix like D using standard NMF,
however, this property will not exist and the two scenarios will not necessarily
be seen as similar. Furthermore, we know from the practice of medicine that
the date at which certain chronic disease gets recorded is a noisy concept, i.e.,
there is an inherent noise in the time of recording a diagnosis. For instance,
a one’s hypertension diagnosis can be delayed by months or years due to one
ignoring the symptoms and/or delaying a doctor visit; or, diseases such de-
mentia are known to have long preclinical periods, where patients who visit
their doctors less regularly are on average more likely to have their diagnosis
delayed.
Therefore, in a second adjustment of Dp, and in order to tackle tempo-
ral forgetting of NMF and sparsity of the data, and take into account the
noise/uncertainty we have around the age that a particular disease is recorded
at, we smooth each column of Dm, using a Gaussian filter with σ = 3 (in order
to be able to learn patterns of diseases even when they are far apart). Figure 3
illustrates the effect of both these adjustments (DF-IPF and smoothing) on
Dp for an example patient.
Before we carry out the NMF analysis, we perform one last step: concate-
nating theDp matrices in age dimension to formD (i.e.,D = [D1,D2, ...,DN ]);
a (T ∗N)×C matrix. In other words, we assume that the relationship among
diseases (i.e., the disease clusters) are in common among patients at all times,
and it is their expression in different people at different ages that varies. De-
composing D to Q MMPs, makes A a (T ∗ N) × Q matrix and B a Q × C
matrix. A row in B will be an MMP’s disease cluster, and a column in A
is an MMP’s time course over patients during their life. See Figure 4 for an
illustration of this process.
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Fig. 3: The effect of adjustments on Dp. In (a), we show a sample Dp, where
the patient had 6 diseases. The result of the DF-IPF adjustment is shown
in (b), which can be seen visually as additional heat in the matrix, due to
further strengthening of the cells that correspond to rare diseases. Lastly,
when smoothed for each age year, as shown in (c), we see a less sparse Dp,
where values of the nearby ages are similar for a given diseases.
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Fig. 4: An illustration of formation and decomposition of disease matrix D.
2.5 Ascendency Analysis
One of the goals of multimorbidity analyses is to conclude how the presence of a
disease or a disease cluster can increase the chance of another disease or disease
cluster. This is essentially what network models do; a comprehensive study and
review of a range of such techniques (for when the data from nodes/variables is
available in the form of time-/event-course) can be found in Smith et al [41]. On
the other hand, each MMP from our approach consists of a disease cluster and
a pseudo time course (a patient-age course, to be more specific); for brevity we
refer to the latter as time course. Therefore, in order to show the strength of our
approach in providing the data for such follow-up studies of multimorbidity,
we next employed a simple technique, which was introduced by Patel et al [34]
for the study of the networks in the brain, for mining the network structure
among MMPs. This idea is illustrated in Figure 5.
Imagine we have two MMPs, for which time courses v and w, are binary
(say, via an appropriate thresholding applied to the continuous time course
resulting from our NMF analysis). Now, if v and w are active together and in-
active together, we consider them associated/connected. This concept is mea-
sured by κv,w ∈ [−1, 1], and can be seen as an undirected edge in a network;
κv,w is 1 when the joint activation probability of v and w is the highest, -1
when the joint activation probability or the joint inactivation probability is
nil, and 0 when v and w are statistically independent. Given the connectivity
between v and w, if v exhibits elevated activity for a subset of the period in
which w exhibits elevated activity, we consider w to be ascendant to v and
vice versa. This is measured by τv,w ∈ [−1, 1], and can be seen as a directional
edge in a network; τv,w > 0 means that v is ascendant to w and τv,w < 0
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Fig. 5: Three MMP pairs (a1,b1), (a2,b2), and (a3,b3) are illustrated, each with
a different hierarchical relationship. As the slope of the line from the origin
to (P (Aa), P (Ab)) gets further from 1, the degree of ascendancy between the
MMP pair increases. Credits to Patel et al. [34]
means that w is ascendant to v. We refer readers to the original paper for
more details on the methods.
3 Results
As explained earlier, we first formed D and used NMF to decompose it. Given
that our implementation of NMF requires the number of factors to be given,
we used cophenetic correlation coefficient to determine it; the result is shown
in Figure 6. Based on the results we observed from a group of 100K randomly-
selected patients, we chose the Q value of 34 as the optimal rank for the NMF.
Given that our approach does not explicitly model gender, we decided to
carry out the analysis separately for men and women, In our data, we have
14 Hassaine et al.
5 10 15 20 25 30 35 40
Rank
0.75
0.80
0.85
0.90
0.95
1.00
Co
ph
en
et
ic 
co
rre
la
tio
n 
co
ef
fic
ie
nt
Fig. 6: The change in cophenetic coefficient (y axis) as a function of number
of factors (x axis). As can be seen, 34 seems to be the optimal number for the
number of factors that NMF will decompose D into.
994,563 male and 1,209,615 female patients; Figure 7 shows the heatmap in
which each column corresponds to disease clusters that result from NMF (i.e.,
matrix B). Corresponding to each of these clusters we have a time course
that has one value for every patient-age, which shows how a cluster has been
expressed in that patient at that age (see Figure 8 for an example visualisation
of this time series).
The components identified by our method are summarised in Table 3 for
male patients and Table 4 for female patients. These tables give for each MMP,
the top 3 diseases and their weights.
As discussed, while disease clusters are important, their trajectories over
time (plus their influence on each other) is also important. One of the advan-
tages of our approach is its ability to provide a time course for each disease
clusters; treating each cluster as a node, this time course opens the door to
a range of network modelling techniques that can help mine the patterns of
interactions among the diseases. In this study, we used ascendancy analysis
(described in Section 2.5) that was shown to be one of the most powerful
techniques for mining directed and undirected edges in a network. Given that
it requires the time courses to be binary, we binarised the time courses cor-
responding to each disease cluster by thresholding it at 5% of its maximum
value (see Figure 8 for an illustration). Functional dependency and ascendency
between different MMPs, obtained through κ and τ , is illustrated in Figure 9.
If we only take the MMP pairs with high κ values, and define the direction
of the edge between each pair using τ , a network can be achieved as shown
in Figures 10 and 11. In these figures, we chose a threshold for κ, so that the
obtained graph has 30 nodes; not too high to make interpretation difficult,
and not too low to make the results less useful for clinical usability.
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Table 3: Identified disease clusters for male patients.
1 J09-J18: Influenza and pneumonia (1.00)
J90-J94: Other diseases of pleura (0.20)
J20-J22: Other acute lower respiratory infections (0.18)
18 I60-I69: Cerebrovascular diseases (1.00)
G40-G47: Episodic and paroxysmal disorders (0.43)
G80-G83: Cerebral palsy and other paralytic syndromes
(0.37)
2 N40-N53: Diseases of male genital organs (1.00)
N30-N39: Other diseases of urinary system (0.17)
A50-A64: Infections with a predominantly sexual mode of
transmission (0.10)
19 H30-H36: Disorders of choroid and retina (1.00)
H43-H45: Disorders of vitreous body and globe (0.49)
H40-H42: Glaucoma (0.15)
3 H65-H75: Diseases of middle ear and mastoid (1.00)
H90-H95: Other disorders of ear (0.50)
J00-J06: Acute upper respiratory infections (0.14)
20 E08-E14: Diabetes mellitus (1.00)
E15-E16: Other disorders of glucose regulation and pan-
creatic internal secretion (0.30)
E65-E68: Obesity and other hyperalimentation (0.27)
4 A30-A49: Other bacterial diseases (1.00)
J90-J94: Other diseases of pleura (0.21)
E65-E68: Obesity and other hyperalimentation (0.16)
21 N20-N23: Urolithiasis (1.00)
N10-N16: Renal tubulo-interstitial diseases (0.28)
N30-N39: Other diseases of urinary system (0.15)
5 C00-C97: Malignant neoplasms (1.00)
D37-D49: Neoplasms of uncertain or unknown behaviour
(0.46)
D00-D09: In situ neoplasms (0.31)
22 L40-L45: Papulosquamous disorders (1.00)
E65-E68: Obesity and other hyperalimentation (0.65)
F10-F19: Mental and behavioural disorders due to psy-
choactive substance use (0.19)
6 I80-I89: Diseases of veins, lymphatic vessels and lymph
nodes, not elsewhere classified (1.00)
I26-I28: Pulmonary heart disease and diseases of pul-
monary circulation (0.19)
L00-L08: Infections of the skin and subcutaneous tissue
(0.14)
23 L55-L59: Radiation-related disorders of the skin and sub-
cutaneous tissue (1.00)
L80-L99: Other disorders of the skin and subcutaneous
tissue (0.35)
B00-B09: Viral infections characterized by skin and mu-
cous membrane lesions (0.15)
7 D60-D64: Aplastic and other anaemias (1.00)
D50-D53: Nutritional anaemias (0.91)
D70-D77: Other diseases of blood and blood-forming or-
gans (0.85)
24 E70-E90: Metabolic disorders (1.00)
I10-I15: Hypertensive diseases (0.09)
K70-K77: Diseases of liver (0.09)
8 F50-F59: Behavioural syndromes associated with physio-
logical disturbances and physical factors (1.00)
G40-G47: Episodic and paroxysmal disorders (0.07)
M60-M79: Soft tissue disorders (0.07)
25 H53-H54: Visual disturbances and blindness (1.00)
H15-H22: Disorders of sclera, cornea, iris and ciliary body
(0.26)
H55-H59: Other disorders of eye and adnexa (0.12)
9 N17-N19: Renal failure (1.00)
I30-I52: Other forms of heart disease (0.85)
I95-I99: Other and unspecified disorders of the circulatory
system (0.46)
26 I10-I15: Hypertensive diseases (1.00)
E65-E68: Obesity and other hyperalimentation (0.27)
H80-H83: Diseases of inner ear (0.18)
10 K50-K52: Noninfective enteritis and colitis (1.00)
K55-K64: Other diseases of intestines (0.17)
L60-L75: Disorders of skin appendages (0.08)
27 K80-K87: Disorders of gallbladder, biliary tract and pan-
creas (1.00)
K70-K77: Diseases of liver (0.40)
K20-K31: Diseases of oesophagus, stomach and duodenum
(0.17)
11 F30-F39: Mood [affective] disorders (1.00)
G30-G32: Other degenerative diseases of the nervous sys-
tem (0.96)
F40-F48: Neurotic, stress-related and somatoform disor-
ders (0.71)
28 H60-H62: Diseases of external ear (1.00)
H90-H95: Other disorders of ear (0.40)
G50-G59: Nerve, nerve root and plexus disorders (0.37)
12 I20-I25: Ischaemic heart diseases (1.00)
I30-I52: Other forms of heart disease (0.23)
J20-J22: Other acute lower respiratory infections (0.08)
29 F10-F19: Mental and behavioural disorders due to psy-
choactive substance use (1.00)
K00-K14: Diseases of oral cavity, salivary glands and jaws
(0.93)
B95-B98: Bacterial, viral and other infectious agents
(0.47)
13 B85-B89: Pediculosis, acariasis and other infestations
(1.00)
L20-L30: Dermatitis and eczema (0.20)
L00-L08: Infections of the skin and subcutaneous tissue
(0.15)
30 B25-B34: Other viral diseases (1.00)
J00-J06: Acute upper respiratory infections (0.13)
H80-H83: Diseases of inner ear (0.13)
14 D10-D36: Benign neoplasms (1.00)
L80-L99: Other disorders of the skin and subcutaneous
tissue (0.26)
L60-L75: Disorders of skin appendages (0.18)
31 K90-K95: Other diseases of the digestive system (1.00)
B00-B09: Viral infections characterized by skin and mu-
cous membrane lesions (0.56)
K20-K31: Diseases of oesophagus, stomach and duodenum
(0.23)
15 K20-K31: Diseases of oesophagus, stomach and duodenum
(1.00)
J40-J47: Chronic lower respiratory diseases (0.94)
J30-J39: Other diseases of upper respiratory tract (0.92)
32 H10-H13: Disorders of conjunctiva (1.00)
H00-H06: Disorders of eyelid, lacrimal system and orbit
(0.93)
H55-H59: Other disorders of eye and adnexa (0.80)
16 K40-K46: Hernia (1.00)
K20-K31: Diseases of oesophagus, stomach and duodenum
(0.16)
J40-J47: Chronic lower respiratory diseases (0.09)
33 H25-H28: Disorders of lens (1.00)
H40-H42: Glaucoma (0.50)
H15-H22: Disorders of sclera, cornea, iris and ciliary body
(0.13)
17 A00-A09: Intestinal infectious diseases (1.00)
G40-G47: Episodic and paroxysmal disorders (0.11)
K55-K64: Other diseases of intestines (0.09)
34 I70-I79: Diseases of arteries, arterioles and capillaries
(1.00)
J40-J47: Chronic lower respiratory diseases (0.10)
L80-L99: Other disorders of the skin and subcutaneous
tissue (0.08)
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Table 4: Identified disease clusters for female patients.
1 I30-I52: Other forms of heart disease (1.00)
I20-I25: Ischaemic heart diseases (0.54)
I60-I69: Cerebrovascular diseases (0.25)
18 E00-E07: Disorders of thyroid gland (1.00)
I10-I15: Hypertensive diseases (0.12)
E70-E90: Metabolic disorders (0.08)
2 A00-A09: Intestinal infectious diseases (1.00)
G50-G59: Nerve, nerve root and plexus disorders (0.36)
K20-K31: Diseases of oesophagus, stomach and duodenum
(0.09)
19 G30-G32: Other degenerative diseases of the nervous sys-
tem (1.00)
F10-F19: Mental and behavioural disorders due to psy-
choactive substance use (0.24)
F40-F48: Neurotic, stress-related and somatoform disor-
ders (0.22)
3 H00-H06: Disorders of eyelid, lacrimal system and orbit
(1.00)
J40-J47: Chronic lower respiratory diseases (0.52)
H10-H13: Disorders of conjunctiva (0.24)
20 I80-I89: Diseases of veins, lymphatic vessels and lymph
nodes, not elsewhere classified (1.00)
L00-L08: Infections of the skin and subcutaneous tissue
(0.18)
L80-L99: Other disorders of the skin and subcutaneous
tissue (0.17)
4 H55-H59: Other disorders of eye and adnexa (1.00)
H10-H13: Disorders of conjunctiva (0.32)
H15-H22: Disorders of sclera, cornea, iris and ciliary body
(0.21)
21 N80-N98: Noninflammatory disorders of female genital
tract (1.00)
D10-D36: Benign neoplasms (0.68)
G50-G59: Nerve, nerve root and plexus disorders (0.41)
5 N60-N65: Disorders of breast (1.00)
C00-C97: Malignant neoplasms (0.16)
B35-B49: Mycoses (0.15)
22 M80-M94: Osteopathies and chondropathies (1.00)
M30-M36: Systemic connective tissue disorders (0.12)
K20-K31: Diseases of oesophagus, stomach and duodenum
(0.12)
6 K00-K14: Diseases of oral cavity, salivary glands and jaws
(1.00)
H10-H13: Disorders of conjunctiva (0.59)
H53-H54: Visual disturbances and blindness (0.24)
23 E20-E35: Disorders of other endocrine glands (1.00)
H15-H22: Disorders of sclera, cornea, iris and ciliary body
(0.72)
L40-L45: Papulosquamous disorders (0.18)
7 J09-J18: Influenza and pneumonia (1.00)
J20-J22: Other acute lower respiratory infections (0.17)
G40-G47: Episodic and paroxysmal disorders (0.16)
24 H65-H75: Diseases of middle ear and mastoid (1.00)
H90-H95: Other disorders of ear (0.39)
H60-H62: Diseases of external ear (0.31)
8 H80-H83: Diseases of inner ear (1.00)
H90-H95: Other disorders of ear (0.16)
H60-H62: Diseases of external ear (0.10)
25 B85-B89: Pediculosis, acariasis and other infestations
(1.00)
B35-B49: Mycoses (0.26)
L20-L30: Dermatitis and eczema (0.22)
9 N30-N39: Other diseases of urinary system (1.00)
E70-E90: Metabolic disorders (0.47)
J20-J22: Other acute lower respiratory infections (0.38)
26 E50-E64: Other nutritional deficiencies (1.00)
D50-D53: Nutritional anaemias (0.21)
L55-L59: Radiation-related disorders of the skin and sub-
cutaneous tissue (0.11)
10 D60-D64: Aplastic and other anaemias (1.00)
D50-D53: Nutritional anaemias (0.66)
K90-K95: Other diseases of the digestive system (0.35)
27 K80-K87: Disorders of gallbladder, biliary tract and pan-
creas (1.00)
K20-K31: Diseases of oesophagus, stomach and duodenum
(0.30)
K40-K46: Hernia (0.26)
11 K50-K52: Noninfective enteritis and colitis (1.00)
K55-K64: Other diseases of intestines (0.16)
K90-K95: Other diseases of the digestive system (0.14)
28 N17-N19: Renal failure (1.00)
I10-I15: Hypertensive diseases (0.39)
E08-E14: Diabetes mellitus (0.37)
12 H25-H28: Disorders of lens (1.00)
H53-H54: Visual disturbances and blindness (0.89)
H30-H36: Disorders of choroid and retina (0.69)
29 I70-I79: Diseases of arteries, arterioles and capillaries
(1.00)
M30-M36: Systemic connective tissue disorders (0.36)
L40-L45: Papulosquamous disorders (0.20)
13 F30-F39: Mood [affective] disorders (1.00)
F40-F48: Neurotic, stress-related and somatoform disor-
ders (0.68)
G40-G47: Episodic and paroxysmal disorders (0.45)
30 D70-D77: Other diseases of blood and blood-forming or-
gans (1.00)
D50-D53: Nutritional anaemias (0.24)
K20-K31: Diseases of oesophagus, stomach and duodenum
(0.10)
14 E65-E68: Obesity and other hyperalimentation (1.00)
E08-E14: Diabetes mellitus (0.41)
I10-I15: Hypertensive diseases (0.21)
31 B00-B09: Viral infections characterized by skin and mu-
cous membrane lesions (1.00)
L55-L59: Radiation-related disorders of the skin and sub-
cutaneous tissue (0.29)
K20-K31: Diseases of oesophagus, stomach and duodenum
(0.19)
15 N10-N16: Renal tubulo-interstitial diseases (1.00)
N20-N23: Urolithiasis (0.25)
N30-N39: Other diseases of urinary system (0.12)
32 H49-H52: Disorders of ocular muscles, binocular move-
ment, accommodation and refraction (1.00)
C00-C97: Malignant neoplasms (0.32)
G20-G26: Extrapyramidal and movement disorders (0.20)
16 L50-L54: Urticaria and erythema (1.00)
L20-L30: Dermatitis and eczema (0.18)
L60-L75: Disorders of skin appendages (0.15)
33 N70-N77: Inflammatory diseases of female pelvic organs
(1.00)
B35-B49: Mycoses (0.17)
N80-N98: Noninflammatory disorders of female genital
tract (0.17)
17 B95-B98: Bacterial, viral and other infectious agents
(1.00)
J30-J39: Other diseases of upper respiratory tract (0.23)
B35-B49: Mycoses (0.21)
34 B25-B34: Other viral diseases (1.00)
H60-H62: Diseases of external ear (0.35)
J30-J39: Other diseases of upper respiratory tract (0.33)
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4 Conclusions and Discussion
In this study, we employed a well-known matrix factorisation technique (i.e.,
NMF) to mine the MMPs from one of the largest EHR datasets in the world
(i.e., CPRD). The key reason behind this research was to provide a solution for
the shortcomings of the state-of-the-art data-driven multimorbidity research.
To be more specific, our study attempted to build on the past studies’ learn-
ings, while minimising risks such as using relatively small data, relying on a
narrow observation window, focusing on a small number of diseases, and solely
extracting the disease clusters (instead of also extracting their trajectories and
how they interact with each other over time).
Our approach is exploratory (or, data-driven) and hence the results will re-
quire thorough clinical validation. Therefore, in a follow-up analysis, we com-
pared the MMPs resulting from our analysis with multimorbidity patterns
published by other studies that went through thorough clinical validations;
more specifically, we considered the study by Jensen et al. for which the list
of directional ICD-10 diagnosis pairs are provided [14]. For the comparison
to hold, for each ICD-10 code we generated the corresponding ICD-10 sub-
chapter. After excluding pairs where the two ICD-10 sub-chapters are the
same, this results in 1,556 unique ICD-10 sub-chapter pairs. Next, for each
MMP we considered the top 10 diseases. Out of 1,556 ICD-10 sub-chapter
pairs by Jensen et al., 411 pairs (26.4%) belong to the top 10 diseases of at
least one of the 34 obtained MMPs of male patients, that is 1.879 higher (95%
CI 1.866-1.892) than what would be obtained through random sampling. Sim-
ilarly, 430 pairs (27.6%) belong to the top 10 diseases of at least one of the 34
obtained MMPs of female patients, which is 1.969 higher (95% CI 1.956-1.983)
than what would be obtained through random sampling. When considering the
top 3 diseases, the overlap will be 3.861 higher than random sampling (95%
CI 3.783-3.939) for male patients and 3.962 (95% CI 3.880-4.045) for female
patients.
Furthermore, to clinically validate our ascendency results, we have com-
puted the number of pairs by Jensen et al. that traverse our ascendency graphs
when choosing κ in a similar way to figures 10 and 11 and when considering
the top 10 diseases for each MMP. These were 328 for male patients, which is
higher than random sampling by a factor of 1.629 (95% CI 1.615-1.644) and
320 for female patients, which is higher than random sampling by a factor of
1.431 (95% CI 1.420-1.443). When considering the top 3 diseases, those num-
ber become 45 for male patients, higher than random sampling by a factor of
2.468 (95% CI 2.411-2.526) and 48 for female patients, higher than random
sampling by a factor of 2.277 (95% CI 2.230-2.325). All these validate the fact
that our approach, despite being purely data-driven, shows strong correspon-
dence to some of the reliable MMP studies that have been clinically validated.
Despite this, we believe that the field will benefit from future research into
a more thorough clinical investigation of the results from the approach we
introduced.
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An important objective of multimorbidity analyses is to conclude a dis-
ease network, which summarises how diseases interact with one another and
influence each other’s trajectories. While network models have the potential
to solve such a problem, if given the time courses for diseases, the definition
of nodes can be a challenge for researchers. As Table 2 shows, if we operate
in the ICD-10 universe, we can see scenarios where the network can have any-
thing ranging from 22 nodes to 10,138 nodes; prior to starting the network
analysis, one needs to make this decision that at what level of this hierarchy
will they define the diseases and hence nodes. We know from the network
modelling literature that the search space for finding the best network is of
a super-exponential size on the number of nodes (i.e., O(n!2(
n
2))) [37]. This
makes the optimisation for learning a network of 10K nodes a huge challenge;
both in terms of data (relatively small number of patients, and low preva-
lence and hence cooccurrence of most diseases at this level) and computing.
On the other hand, using ICD-10 chapters, which will result in network with
22 nodes, is likely to lead to results that are hard to be clinically meaning-
ful/interpretable; due to the heterogeneity of the diseases they each contain.
Operating at levels such as sub-chapters and 2-digit ICD-10 codes is likely to
have many highly correlated/co-occurring nodes that might make sense to be
combined (particularly, given the data and computing challenges that we face
when learning large networks).
Therefore, in this study, we introduced a new concept for the node: the
disease clusters resulting from the NMF. This definition of nodes has a few
advantages. Firstly, as our analysis suggests, it leads to a relatively small
number of nodes, for which the corresponding network will be easier to learn.
Secondly, from an empirical point of view, given that such nodes are driven by
diseases that usually cooccur, splitting them into sub-nodes is not likely to be
the source of any advantage (specially that such a split will make the network
more complex and hence more difficult to learn). And lastly, from a clinical
way of thinking, we are implying that diseases tend to happen in clusters
and what the network will tell us is the influence of one cluster on another,
given the rest of the clusters. This is in correspondence with what many in the
clinical world have been arguing for that the definition of diseases today might
not be the most accurate one (and hence various research on phenomapping
of the diseases). Based on all these, we carried out our analysis and derived
a network, using a simple and yet powerful technique known as ascendancy
analysis. Of course, the data from our NMF approach is equally useful for any
other network model (e.g., Bayesian networks), and hence there is need for
follow-up research on the use of alternative network modelling techniques (an
exhaustive list of such techniques have been used and compared in Smith et
al [41]).
As in most such analyses, our modelling pipeline relied on a mix of choices
we made; from preprocessing to factorisation technique and beyond. For in-
stance, NMF has a range of different implementations; a follow-up research
on comparing different implementations of NMF can surely improve the ap-
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proach we introduced. Furthermore, the data preprocessing we introduced,
from smoothing to adjustment for count can all be done with some differences
that can be subject of future research. Lastly, our approach was focused on D
as defined in Section 2. The earlier works, however, have introduced more con-
cepts (e.g., measurements and medications) to the starting matrix, and some
even went further and introduced a tensor as their starting point. A combina-
tion of our approach and such works can lead to richer multimorbidity analyses
that not only can take time/age into account, but also can benefit from ad-
ditional concepts and interventions that do influence the disease clusters and
their trajectories.
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A00-A09: Intestinal infectious diseases
A15-A19: Tuberculosis
A20-A28: Certain zoonotic bacterial diseases
A30-A49: Other bacterial diseases
A50-A64: Infections with a predominantly sexual mode of transmission
A65-A69: Other spirochaetal diseases
A70-A74: Other diseases caused by chlamydiae
A75-A79: Rickettsioses
A80-A89: Viral infections of the central nervous system
A90-A99: Arthropod-borne viral fevers and viral haemorrhagic fevers
B00-B09: Viral infections characterized by skin and mucous membrane lesions
B15-B19: Viral hepatitis
B20-B24: Human immunodeficiency virus [HIV] disease
B25-B34: Other viral diseases
B35-B49: Mycoses
B50-B64: Protozoal diseases
B65-B83: Helminthiases
B85-B89: Pediculosis, acariasis and other infestations
B90-B94: Sequelae of infectious and parasitic diseases
B95-B98: Bacterial, viral and other infectious agents
B99-B99: Other infectious diseases
C00-C97: Malignant neoplasms
D00-D09: In situ neoplasms
D10-D36: Benign neoplasms
D37-D49: Neoplasms of uncertain or unknown behaviour
D50-D53: Nutritional anaemias
D55-D59: Haemolytic anaemias
D60-D64: Aplastic and other anaemias
D65-D69: Coagulation defects, purpura and other haemorrhagic conditions
D70-D77: Other diseases of blood and blood-forming organs
D80-D89: Certain disorders involving the immune mechanism
E00-E07: Disorders of thyroid gland
E08-E14: Diabetes mellitus
E15-E16: Other disorders of glucose regulation and pancreatic internal secretion
E20-E35: Disorders of other endocrine glands
E40-E46: Malnutrition
E50-E64: Other nutritional deficiencies
E65-E68: Obesity and other hyperalimentation
E70-E90: Metabolic disorders
F00-F09: Organic, including symptomatic, mental disorders
F10-F19: Mental and behavioural disorders due to psychoactive substance use
F20-F29: Schizophrenia, schizotypal and delusional disorders
F30-F39: Mood [affective] disorders
F40-F48: Neurotic, stress-related and somatoform disorders
F50-F59: Behavioural syndromes associated with physiological disturbances and physical factors
F60-F69: Disorders of adult personality and behaviour
F70-F79: Mental retardation
F80-F89: Disorders of psychological development
F90-F98: Behavioural and emotional disorders with onset usually occurring in childhood and adolescence
F99-F99: Unspecified mental disorder
G00-G09: Inflammatory diseases of the central nervous system
G10-G14: Systemic atrophies primarily affecting the central nervous system
G20-G26: Extrapyramidal and movement disorders
G30-G32: Other degenerative diseases of the nervous system
G35-G37: Demyelinating diseases of the central nervous system
G40-G47: Episodic and paroxysmal disorders
G50-G59: Nerve, nerve root and plexus disorders
G60-G64: Polyneuropathies and other disorders of the peripheral nervous system
G70-G73: Diseases of myoneural junction and muscle
G80-G83: Cerebral palsy and other paralytic syndromes
G89-G99: Other disorders of the nervous system
H00-H06: Disorders of eyelid, lacrimal system and orbit
H10-H13: Disorders of conjunctiva
H15-H22: Disorders of sclera, cornea, iris and ciliary body
H25-H28: Disorders of lens
H30-H36: Disorders of choroid and retina
H40-H42: Glaucoma
H43-H45: Disorders of vitreous body and globe
H46-H48: Disorders of optic nerve and visual pathways
H49-H52: Disorders of ocular muscles, binocular movement, accommodation and refraction
H53-H54: Visual disturbances and blindness
H55-H59: Other disorders of eye and adnexa
H60-H62: Diseases of external ear
H65-H75: Diseases of middle ear and mastoid
H80-H83: Diseases of inner ear
H90-H95: Other disorders of ear
I00-I02: Acute rheumatic fever
I05-I09: Chronic rheumatic heart diseases
I10-I15: Hypertensive diseases
I20-I25: Ischaemic heart diseases
I26-I28: Pulmonary heart disease and diseases of pulmonary circulation
I30-I52: Other forms of heart disease
I60-I69: Cerebrovascular diseases
I70-I79: Diseases of arteries, arterioles and capillaries
I80-I89: Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified
I95-I99: Other and unspecified disorders of the circulatory system
J00-J06: Acute upper respiratory infections
J09-J18: Influenza and pneumonia
J20-J22: Other acute lower respiratory infections
J30-J39: Other diseases of upper respiratory tract
J40-J47: Chronic lower respiratory diseases
J60-J70: Lung diseases due to external agents
J80-J84: Other respiratory diseases principally affecting the interstitium
J85-J86: Suppurative and necrotic conditions of lower respiratory tract
J90-J94: Other diseases of pleura
J95-J99: Other diseases of the respiratory system
K00-K14: Diseases of oral cavity, salivary glands and jaws
K20-K31: Diseases of oesophagus, stomach and duodenum
K35-K38: Diseases of appendix
K40-K46: Hernia
K50-K52: Noninfective enteritis and colitis
K55-K64: Other diseases of intestines
K65-K67: Diseases of peritoneum
K70-K77: Diseases of liver
K80-K87: Disorders of gallbladder, biliary tract and pancreas
K90-K95: Other diseases of the digestive system
L00-L08: Infections of the skin and subcutaneous tissue
L10-L14: Bullous disorders
L20-L30: Dermatitis and eczema
L40-L45: Papulosquamous disorders
L50-L54: Urticaria and erythema
L55-L59: Radiation-related disorders of the skin and subcutaneous tissue
L60-L75: Disorders of skin appendages
L80-L99: Other disorders of the skin and subcutaneous tissue
M00-M25: Arthropathies
M30-M36: Systemic connective tissue disorders
M40-M54: Dorsopathies
M60-M79: Soft tissue disorders
M80-M94: Osteopathies and chondropathies
M95-M99: Other disorders of the musculoskeletal system and connective tissue
N00-N08: Glomerular diseases
N10-N16: Renal tubulo-interstitial diseases
N17-N19: Renal failure
N20-N23: Urolithiasis
N25-N29: Other disorders of kidney and ureter
N30-N39: Other diseases of urinary system
N40-N53: Diseases of male genital organs
N60-N65: Disorders of breast
N70-N77: Inflammatory diseases of female pelvic organs
N80-N98: Noninflammatory disorders of female genital tract
N99-N99: Other disorders of the genitourinary system
Q00-Q07: Congenital malformations of the nervous system
Q10-Q18: Congenital malformations of eye, ear, face and neck
Q20-Q28: Congenital malformations of the circulatory system
Q30-Q34: Congenital malformations of the respiratory system
Q35-Q37: Cleft lip and cleft palate
Q38-Q45: Other congenital malformations of the digestive system
Q50-Q56: Congenital malformations of genital organs
Q60-Q64: Congenital malformations of the urinary system
Q65-Q79: Congenital malformations and deformations of the musculoskeletal system
Q80-Q89: Other congenital malformations
Q90-Q99: Chromosomal abnormalities, not elsewhere classified
Fig. 7: Multi-morbidity components of male patients on the left side and female
patients on the right side (gamma correction is applied so that small values
are visible). Note that we show a transposed version (BT ) of B matrices for
clarity.
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(a) Disease cluster for MMP #9 for male patients, which shows the strength of each disease association with it.
(b) 9th MMP time course for all patients
(c) Normalised 9th MMP’ time course for two patients and its binarised version (d) Average 9th MMP’ time course across all patients
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Fig. 8: Example MMP and its corresponding time courses.
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Fig. 9: Mean κ and τ for all pairs of MMP components for both male and female
patients. (κ’s diagonal whitened so that other values are easy to observe). Note
that κ is symmetric while τ is asymmetric.
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Fig. 10: Network of MMP components for male patients. Edges are coloured
with the colour of the node they originate from.
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Fig. 11: Network of MMP components for female patients. Edges are coloured
with the colour of the node they originate from.
